Monthly research recap
DMT research: July 2026
What July 2026's 10 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.
In July 2026, research on DMT reported positive effects on emotional processing, well-being, and neural plasticity, but evidence is mixed regarding its comparative efficacy and long-term durability. A placebo-controlled trial found that a harmine+DMT combination reduced embarrassment and shame, while open-label data showed sustained improvements in anxiety, life satisfaction, and quality of life in patients with depression. However, animal data indicated that DMT's antidepressant effects were comparable to S-ketamine but not consistently superior, and the overall evidence base remains limited by small samples, open-label designs, and early-stage trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers. 2026 | randomized, double-blind, placebo-controlled crossover trial | 28 | Supports | Combined harmine and DMT significantly reduced embarrassment and shame compared to placebo during a social self-evaluation task, whereas harmine alone did not. |
| Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms 2026 | review | Supports | Argues that recent patent applications for selective 5-HT2A activators, precision aerosol delivery, and structured 5-MeO-DMT regimens indicate a convergence toward scalable and safer psychedelic therapeutics. | |
| Study 35070 | in vitro experimental study | Supports | Brief 24-hour DMT exposure increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated neurotrophin expression including BDNF. | |
| Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells. 2026 | in vitro experimental study | Supports | 24-hour DMT treatment increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated G1 cell-cycle regulators and BDNF expression. | |
| Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression 2026 | open-label clinical trial | 41 | Supports | Inhaled DMT with psychological support was associated with reduced state anxiety, increased life satisfaction, and sustained improvements in quality of life in patients with treatment-resistant depression over 12 months. |
| DMT and Microtubule Coherence Selection: A Testable Model of Informational Throttling in Time Perception 2026 | theoretical or philosophical paper | Unclear | Argues that DMT alters subjective time by modulating microtubule vibrational coherence through 5-HT2A and sigma-1 receptor pathways, slowing a scalar clock field phi. | |
| N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine. 2026 | animal study | Supports | DMT was as effective as S-ketamine in producing rapid and long-lasting antidepressant effects in helpless mice and also showed anxiolytic-like effects. | |
| Reconstituting a two-step pathway for N,N-dimethyltryptamine (DMT) biosynthesis in bacteria 2026 | experimental study | Supports | Reconstructing a two-step bacterial pathway in E. coli produced up to 103 mg/L DMT in complex medium, with methionine supplementation increasing yields 2.8-fold and identifying methylation capacity as a key constraint. | |
| Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review. 2026 | systematic review | 26 | Mixed | The registry landscape for DMT and ayahuasca trials expanded after 2020-2021, dominated by early-stage development with conservative eligibility criteria and a focus on acute safety and subjective effects, while disorder-specific programs beyond depression remain limited. |
| DMT und Ayahuasca / DMT and Ayahuasca 2026 | scientific overview | Unclear | Provides a transdisciplinary overview of DMT and ayahuasca, highlighting five unique features including oral inactivity without an MAO inhibitor, ultra-short duration, ayahuasca as a plant combination, endogenous occurrence, and the Gonzales v. O Centro ruling. |
Points of agreement
- DMT shows potential for reducing negative emotions and improving well-being in clinical and preclinical studies.
- DMT promotes neural plasticity, as evidenced by increased proliferation of human neural stem cells and upregulation of BDNF.
- The clinical trial landscape for DMT is expanding but remains early-stage, focusing on safety and subjective effects.
Conflicts
- One study found DMT reduced embarrassment and shame, while another found no significant difference between DMT and harmine alone on these measures.
- Animal data showed DMT's antidepressant effects lasted longer than S-ketamine in some tests, but S-ketamine had longer-lasting effects in others.
- The theoretical model proposes a mechanism for DMT's effects on time perception, but this is not empirically validated and contrasts with more conventional neuroplasticity explanations.
Gaps
- Long-term durability of DMT's effects beyond 12 months is not established.
- Most clinical trials are open-label or early-phase, lacking blinded, controlled designs for efficacy.
- The in vitro and animal findings may not translate to humans, and the optimal dose and administration route remain unclear.
- The theoretical model lacks empirical testing and validation.
- The scoping review notes limited disorder-specific programs beyond depression, indicating a gap in research for other psychiatric conditions.